GlassScriptPhysician profile
Huiping Pei
NPI 1184812778
$13,984.58
in general payments reported to CMS, 2019-2025
45 companies · $2,018 in 2025
The $2,018 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $767 · 2021: $3,166 · 2022: $3,046 · 2023: $2,438 · 2024: $2,315 · 2025: $2,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,770.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,928.76 | 2020-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $1,709.34 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,349.13 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,202.24 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $853.08 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Biohaven Pharmaceuticals, INC. | $610.58 | 2020-2021 | |
| Eisai INC. | $411.37 | 2020-2024 | |
| Lundbeck LLC | $389.12 | 2022-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $373.78 | 2020-2024 | Austedo Xr |
| Corcept Therapeutics | $338.55 | 2022-2025 | Korlym |
| Gilead Sciences, INC. | $333.81 | 2021-2025 | |
| Amarin Pharma, INC. | $329.80 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $293.55 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $241.96 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $241.83 | 2021-2025 | Livalo, Seglentis, Zoryve |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huiping Pei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.